News
10-22-2018, 01:31 AM
Merck, known as MSD outside the United States and Canada, today announced the first presentation of preliminary data from a Phase 1 clinical trial evaluating MK-1454, an investigational STING (stimulator of interferon genes) agonist, as monotherapy and in combination with KEYTRUDA (pembrolizumab), Merck's anti-PD-1 therapy, in patients with advanced solid tumors or lymphomas.
More... (https://www.news-medical.net/news/20181022/Merck-presents-MK-1454-Phase-1-data-for-treatment-of-advanced-solid-tumors-or-lymphomas.aspx)
More... (https://www.news-medical.net/news/20181022/Merck-presents-MK-1454-Phase-1-data-for-treatment-of-advanced-solid-tumors-or-lymphomas.aspx)